Cell line development technologies are leveraged dominantly by pharmaceutical companies in drug discovery. Cell lines refer to vitro models that are used across various fields of medical research and the discovery of new drugs. Their experimental usage is determining the genetic properties of cell lines. Biologics and recombinant protein production are key areas where cell line development occurs. The growing precision medicines and targeted treatments have propelled demand for cell line procedures. Derived from plant cells, humans, and animals these complex multicellular organisms are aiding to create next-generation drugs.

The growing biologics field has created space for gene therapies and altered the ways of treating diseases that plagued humans for centuries such as cancer and arthritis. These methods are determined as a major step in improving the efficiency of vitro testing and drug discovery.

The global cell line development market was valued at USD 4,160.42 million in 2019. This industry is further expected to surpass the valuation of USD 11,219.87 million by 2027. Growing cases of cancers and propelling medical research in biologics have spurred demand for cell line development in recent years.